Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    The Aetiology of Hand, Foot and Mouth Disease in Western Australia and the Northern Territory, 2007-2010

    Access Status
    Fulltext not available
    Authors
    Williams, David
    Levy, Avram
    Williams, Simon
    Speers, David
    Date
    2011
    Type
    Conference Paper
    
    Metadata
    Show full item record
    Citation
    Williams, David and Levy, Avram and Williams, Simon and Speers, David. 2011. The Aetiology of Hand, Foot and Mouth Disease in Western Australia and the Northern Territory, 2007-2010, in Y. Kawaoka (ed), IUMS 2011 Sapporo, International Congress of Virology, Sep 11-16 2011, pp. 1-204. Sapporo, Japan: International Union of Microbiological Societies.
    Source Title
    IUMS 2011 Sapporo, International Congress of Virology Final Program
    Source Conference
    IUMS 2011 Sapporo, International Congress of Virology
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/42150
    Collection
    • Curtin Research Publications
    Abstract

    Hand, foot and mouth disease (HFMD) is a common childhood disease characterized by fever and vesicular rash on the palms, feet, and buttocks, and oropharyngeal ulcers. HFMD is associated with infections by species A enteroviruses (EV). In rare cases, EV serotype 71 (EV71) infections are also associated with neurological disease. Surveillance of HFMD in Western Australia (WA) and the Northern Territory is undertaken routinely at PathWest Laboratory Medicine. Molecular testing involves initial screening using a RT-PCR targeting the 5'UTR of the EV genome. Amplicons are sequenced and their identities determined using BLAST. Where highest matches to EV71 or other EVs of interest are found, additional real-time RT-PCR and/or amplification and sequencing of partial VP1 gene is performed. The predominant serotypes associated with HFMD from January 2007 to December 2010 were EV71 and Coxsackievirus A6 (CAV6). For both serotypes, the majority of infections (74%) occurred in the <4 year age groups. Highest numbers of EV71 infections were found in 2009 (28 cases; with 26 occurring July to December), accounting for 29% of all EV infections detected July-December. Phylogenetic analyses of VP1 demonstrated co-circulation of B5 and C2 subgenogroups of EV71.The recent C2 strains showed closest genetic relationships to strains detected in Perth in 1999, suggesting continuous transmission of this lineage in WA. CAV6 emerged as a major cause of HFMD in WA and NT in 2010, with peak activity occurring from May-December (133 cases). CAV6 was the dominant EV serotype circulating during this time (65% of EVs detected). Phylogenetic analysis of partial VP1 identified three distinct lineages of CAV6, belonging to a single genogroup (G3), which includes emergent epidemic strains from Finland (2008), and indicates movement of this virus between Europe and WA. Interestingly, there was no evidence of onychomadesis (nail-shedding) following CAV6 infections, unlike in recent European epidemics.

    Related items

    Showing items related by title, author, creator and subject.

    • Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia
      Gidding, H.; McCallum, L.; Fathima, P.; Moore, H.; Snelling, Thomas; Blyth, C.; Jayasinghe, S.; Giele, C.; de Klerk, N.; Andrews, R.; McIntyre, P. (2018)
      Background: Most studies use indirect cohort or case-control methods to estimate vaccine effectiveness (VE) of 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease (IPD). ...
    • Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
      Pomat, William; van den Biggelaar, Anita; Phuanukoonnon, Suparat; Francis, Jacinta; Jacoby, Peter; Siba, Peter; Alpers, Michael; Reeder, John; Holt, Patrick; Richmond, Peter; Lehmann, Deborah (2013)
      Background: Approximately 826,000 children, mostly young infants, die annually from invasive pneumococcal disease. A 6-10-14-week schedule of pneumococcal conjugate vaccine (PCV) is efficacious but neonatal PCV may provide ...
    • Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
      Van Den Biggelaar, A.; Richmond, P.; Fuery, A.; Anderson, D.; Opa, C.; Saleu, G.; Lai, M.; Francis, J.; Alpers, Michael Philip; Pomat, W.; Lehmann, D. (2017)
      Trial design: In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.